4 days ago · Some women might not be able to breastfeed after breast cancer treatment, depending on the treatment they received and other factors (see below)
Feb 16, 2022 · Tamoxifen is a drug used to treat breast cancer in both premenopausal women (women who have not yet gone through the menopause) and postmenopausal
Women taking tamoxifen are advised not to breastfeed as it may pass through the bloodstream into the breast milk
Oct 23, 2017 · During active cancer treatments, breastfeeding should be avoided since many cytotoxic drugs are secreted in breast milk
Methods We measured the concentration of tamoxifen and its metabolites by liquid chromatography-tandem mass spectrometry in the milk of a nursing mother that was
It works by blocking the hormone estrogen in breast tissue, which prevents breast cancer cells from spreading or
Patients and methods: The present retrospective analysis included 32 premenopausal women with a diagnosis of estrogen
Worldwide, breast cancer is the most common cancer in women
Many people take this hormonal therapy for five to 10 years to treat or prevent certain types of breast cancer
PURPOSE To determine the updated long-term outcomes of the Addition of Ovarian Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Regain Vaginal Bleeding After Chemotherapy (ASTRRA) trial
Two years of tamoxifen seemed to offer the most survival benefit 5 to 15 years after diagnosis, but continued to offer some benefit more than 15 years after diagnosis
Therefore, this study aimed to evaluate the association of CYP2D6*10 (c
After mastectomy, if there has been reconstructive surgery on the breast and nipple, it may be possible to feed your baby at your breast using a supplemental nursing system
, anastrozole, exemestane or letrozole)
All patients were postmenopausal, and the mean age was 66 (range 61-73) years at the time of the diagnosis of the uterine receptor–positive breast cancer who remain in a premenopausal state or resume ovarian function after chemotherapy
The study treatment was given from years 5 through 10 after the diagnosis — a period when further tamoxifen therapy is not beneficial but when relapses of breast cancer occur
Background: Tamoxifen is one of the medicines for adjuvant endocrine therapy of hormone-dependent breast cancer
For premenopausal women, tamoxifen may be combined with ovarian suppression
Purpose To compare and describe the quality of life (QOL) of women allocated to tamoxifen or exemestane within the Intergroup Exemestane Study (IES)
A prospective randomized controlled trial (POSITIVE) is underway to obtain higher level data on the safety of interrupting endocrine therapy for up to 2 years for childbearing and breastfeeding